Securities & Capital Markets
Representative Initial Public Offerings (IPOs)
- Represented Sera Prognostics in its $80M initial public offering underwritten by Citi, Cowen and William Blair
- Represented Nyxoah S.A. in its $87M initial public offering underwritten by Stifel, Nicolaus & Company, Cantor Fitzgerald & Co., Banque Degroof Petercam SA and Piper Sandler
- Represented Acurx Pharmaceuticals in its $15M initial public offering underwritten by Alexander Capital, L.P.
- Represented NexImmune, Inc. in its $126.5M initial public offering underwritten by Barclays, Raymond James, Cantor Fitzgerald and Allen & Company
- Represented Hydrofarm Holdings Group, Inc. in its $199M initial public offering underwritten by JP Morgan and Stifel
- Galecto, Inc.: represented the underwriters (BofA Securities, SVB Leerink, Credit Suisse and Kempen & Co.) in the $80M initial public offering
- Praxis Precision Medicines, Inc.: represented the underwriters (Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets) in the $190M initial public offering
- Represented Inhibrx, Inc. in its $136.9M initial public offering underwritten by Jefferies LLC, Credit Suisse Securities and Evercore Group
- Represented Viela Bio, Inc. in its $172.6M initial public offering underwritten by Morgan Stanley, Goldman Sachs, Cowen and Guggenheim
- Represented Quanterix Corporation in its $64.1M initial public offering underwritten by JP Morgan, Leerink Partners, Cowen and Company, BTIG and Evercore ISI
- Represented Spero Therapeutics in its $77M initial public offering underwritten by BofA Merrill Lynch, Cowen and Company and Stifel
- Represented G1 Therapeutics, Inc. in its $105M initial public offering underwritten by J.P. Morgan Securities, Cowen and Company, Needham & Company and Wedbush Securities
- Represented NuCana plc in its $114M initial public offering underwritten by Citigroup, Jefferies, Cowen and Company and William Blair
- Represented WAVE Life Sciences in its $102M initial public offering underwritten by Jefferies, Leerink Partners, JMP Securities and Suntrust Robinson Humphrey
- Brainsway Ltd.: represented the underwriters (Cantor, Raymond James, Oppenheimer & Co. and Ladenburg Thalmann) in the $35M initial public offering
- Anchiano Therapeutics Ltd.: represented the underwriters (Oppenheimer & Co., Ladenburg Thalmann and LifeSci Capital) in the $30.5M initial public offering
- Vaccinex Inc.: represented the underwriters (Oppenheimer, BTIG, LLC and Ladenburg Thalmann) in the $39.6M initial public offering
- Neos Therapeutics, Inc.: represented the underwriters (UBS Investment Bank, BMO Capital Markets, RBC Capital Markets and JMP Securities) in the $82.8M initial public offering
- Zosano Pharma Corporation: represented the underwriters (Roth Capital and Ladenburg Thalmann) in the $50M initial public offering
- Calithera Biosciences, Inc.: represented the underwriters (Citigroup, Leerink Partners, Wells Fargo Securities and JMP Securities) in the $80M initial public offering
- Bio Blast Pharma Ltd.: represented the underwriters (Oppenheimer & Co., Roth Capital Partners and BTIG) in the $32.5M initial public offering
- Represented Ruthigen, Inc. in its $20.3M initial public offering underwritten by Dawson James Securities and ViewTrade Securities, Inc.
- Dipexium Pharmaceuticals, Inc.: represented the underwriters (Oppenheimer & Co. and Feltl and Company) in the $33M initial public offering
- Represented NephroGenex, Inc. in its $37.2M initial public offering underwritten by Aegis Capital
- Dicerna Pharmaceuticals, Inc.: represented the underwriters (Jefferies, Leerink, Stifel and Baird) in the $103M initial public offering
Representative Follow-on Public Offerings – Issuer-Side Representation
- Represented G1 Therapeutics, Inc. in its $150M at-the-market offering facility
- Represented F-Star Therapeutics in its $65M public offering underwritten by SVB Leerink, Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC
- Represented Albireo Pharma, Inc. in its $100M at-the-market offering facility
- Represented Quanterix Corporation in its $250M public offering underwritten by Goldman Sachs & Co. LLC, Canaccord Genuity LLC, SVB Leerink LLC and Cowen and Company, LLC
- Represented Dermtech, Inc. in its $125M public offering underwritten by Cowen and Company, LLC, William Blair & Company, LLC, BTIG, LLC, Craig-Hallum Holdings LLC, Oppenheimer & Co. Inc. and Lake Street Capital Markets, LLC
- Represented Molecular Templates, Inc. in its $75M public offering underwritten by BofA Securities, Cowen and Company, Evercore and Barclays
- Represented Wave Life Sciences in its $100M public offering underwritten by Jefferies, SVB Leerink, Mizuho Securities, Truist Securities and H.C. Wainwright and Co.
- Represented NuCana plc in its $80M public offering underwritten by Citigroup, Jefferies, Cowen and Company, William Blair and Truist Securities
- Represented Spero Therapeutics in its $80M public offering underwritten by Cowen and Company, Evercore and Cantor Fitzgerald
- Represented Intra-Cellular Therapies in its $380M public offering underwritten by J.P. Morgan, Goldman Sachs, SVB Leerink, Evercore, Cantor Fitzgerald and Canaccord Genuity
- Represented Quanterix Corporation in its $91M public offering underwritten by SVB Leerink, Cowen and Company and Canaccord Genuity
- Represented Viela Bio, Inc. in its $169.2M public offering underwritten by Morgan Stanley, Goldman Sachs, Cowen and Guggenheim
- Represented Evofem Biosciences Inc. in its $100M public offering underwritten by Morgan Stanley, Piper Sandler, Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC
- Represented Molecular Templates, Inc. in its $58M public offering underwritten by Cowen, Barclays and Stifel
- Represented Intra-Cellular Therapies in its $295M public offering underwritten by J.P. Morgan, Leerink, Evercore, Cantor Fitzgerald, Canaccord Genuity and JMP
- Represented ImmunoGen, Inc. in its $104M public offering underwritten by Jefferies, Cowen and William Blair
- Represented Quanterix Corporation in its $69M public offering underwritten by J.P. Morgan Securities, SVB Leerink and Canaccord Genuity
- Represented X4 Pharmaceuticals, Inc. in its $85.8M public offering underwritten by Cowen, Stifel and Canaccord Genuity
- Represented WAVE Life Sciences in its $150M public offering underwritten by Jefferies, SVB Leerink, Mizuho Securities USA, SunTrust Robinson Humphrey and H.C. Wainwright & Co.
- Represented Molecular Templates, Inc. in its $52M public offering underwritten by Cowen, Evercore ISI, UBS Investment Bank and Laidlaw & Company (UK) Ltd.
- Represented Spero Therapeutics in its $75M public offering underwritten by Cowen, Stifel, Nicolaus & Company and Cantor Fitzgerald
- Represented G1 Therapeutics, Inc. in its $180M public offering underwritten by J.P. Morgan, Cowen, Needham & Company, Wedbush Securities Inc. and BTIG
- Represented ImmunoGen, Inc. in its $150.7M public offering underwritten by J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Canaccord Genuity and H.C. Wainwright & Co.
- Represented Spring Bank Pharmaceuticals, Inc. in its $37.5M public offering underwritten by Jefferies and Piper Jaffray
- Represented Evofem Biosciences Inc. in its $40M public offering underwritten by RBC Capital Markets LLC and Cantor FitzgeraldRepresented G1 Therapeutics, Inc. in its $108M public offering underwritten by J.P. Morgan, Cowen and Company, Needham & Company, Wedbush Securities Inc. and BTIG
- Represented Pieris Pharmaceuticals, Inc. in its $44M public offering underwritten by Jefferies, Cowen and Company and Evercore ISI
- Represented Albireo Pharma, Inc. in its $65M public offering underwritten by Cowen and Company, William Blair & Company, Needham & Company, Wedbush Securities and Roth Capital Partners
Representative Follow-on Public Offerings – Underwriters’ Representation
- Represented the underwriters in the $137.5M public offering of Adicet Bio, Inc. underwritten by Guggenheim Securities
- Represented the underwriters in the $147M public offering of Curis, Inc. underwritten by H.C. Wainwright & Co., LLC, Laidlaw & Company (UK) Ltd., Cantor Fitzgerald & Co. and JonesTrading Institutional Services, LLC
- Represented the underwriters in the $40M public offering of Forte Biosciences, Inc. underwritten by Truist Securities, Inc., Ladenburg Thalmann & Co. Inc., Chardan Capital Markets, LLC and Brookline Capital Markets, LLC
- Represented the underwriters in the $188.5M public offering of Adverum Biotechnologies, Inc. underwritten by SVB Leerink LLC, Goldman Sachs & Co. LLC, Piper Sandler & Co., and Cowen and Company, LLC
- Represented the underwriters in the $492M public offering of Acceleron Pharma Inc. underwritten by JP Morgan Securities, SVB Leerink, Cowen and Company, Barclays, Credit Suisse and Piper Sandler
- Represented the underwriters in the $152M public offering of Mersana Therapeutics underwritten by Cowen and Company, SVB Leerink, Wedbush PacGrow, Baird and H.C. Wainwright & Co.
- Represented the underwriters in the $50M public offering of Trevena, Inc. underwritten by Guggenheim Securities
- Represented the underwriters in the $50M public offering of Soleno Therapeutics, Inc. underwritten by Guggenheim Securities, Oppenheimer & Co. and Maxim Group LLC
- Represented the underwriters in the $140M public offering of Geron Corporation underwritten by Stifel and MTS Health Partners
- Represented the underwriters in the $75M public offering of Axovant Gene Therapies underwritten by SVB Leerink
- Represented the underwriters in the $32M public offering of Misonix, Inc. underwritten by Canaccord Genuity, BTIG and Craig-Hallum Capital Group
- Represented the underwriters in the $225M public offering of uniQure NV underwritten by Goldman Sachs, SVB Leerink, Stifel, Cantor, SunTrust Robinson Humphrey and H.C. Wainwright & Co.
- Represented the underwriters in the $63M public offering of Exicure underwritten by Guggenheim Securities
- Represented the underwriters in the $103M public offering of ArQule, Inc. underwritten by SVB Leerink, RBC Capital Markets, Oppenheimer & Co., Needham, Roth, B. Riley FBR and JonesTrading
- Represented the underwriters in the $97M public offering of Mersana Therapeutics underwritten by SVB Leerink and Wedbush
- Represented the underwriters in the $130.6M public offering of Adverum Biotechnologies, Inc. underwritten by SVB Leerink LLC, Goldman Sachs & Co. LLC, Cowen and LifeSci Capital, LLC
- Represented the underwriters in the $345M public offering of American Depositary Shares of GW Pharmaceuticals plc underwritten by Goldman Sachs, Morgan Stanley, J.P. Morgan and Cowen and Company
- Represented the underwriters in the $115M public offering of Dicerna Pharmaceuticals, Inc. underwritten by Stifel Nicolaus, Citigroup, H.C. Wainwright & Co. and SunTrust Robinson Humphrey
- Represented the underwriters in the $75M public offering of Myovant Sciences Ltd. underwritten by J.P. Morgan Securities, Goldman Sachs, Barclays Capital, JMP Securities LLC and Robert W. Baird & Co.
- Represented the underwriters in the $70M public offering of ArQule, Inc. underwritten by Leerink Partners, Needham & Company, Roth Capital Partners, B.Riley FBR and Jones Trading Institutional Trading Services LLC
- Represented the underwriters in the $65M public offering of Vericel Corporation underwritten by Leerink Partners, BTIG and Ladenburg Thalmann
- Represented the underwriters in the $46M public offering of Sesen Bio, Inc. underwritten by Jefferies and Canaccord Genuity
- Represented the underwriters in the $57.5M public offering of Calithera underwritten by SVB Leerink, BTIG and Ladenburg Thalmann
- Represented the underwriters in the $147.5M public offering of uniQure NV underwritten by Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan and H.C. Wainwright & Co.
- Represented the underwriters in the $40.1M public offering of miRagen Therapeutics, Inc. underwritten by Jefferies, Evercore ISI, Deutsche Bank Securities, Wedbush PacGrow and Oppenheimer & Co.
Case Study
When Daré Bioscience Operations, Inc. first became a Mintz client, it was a private health care company working to develop innovative product candidates in women’s reproductive health. Due to the significant expenses associated with product development and regulatory compliance for innovative drug, device, and combination products, the San Diego-based company sought to raise capital through entering the public markets. Since becoming a public company, Daré Bioscience has in-licensed multiple exciting product candidates focused on women’s sexual health, vaginal health, fertility, and contraception and prioritized a goal of achieving FDA marketing approval for one or more products.
Case Study
The Mintz team accomplished this negotiation through its long-standing relationship with Aspen, which dates back to 2010, and its comprehensive understanding of the company’s goals. Mintz represented Aspen during its initial public offering (IPO) as well as through numerous additional financings and strategic partnerships targeting new product and market opportunities.
Case Study
Mintz is advising Vicarious Surgical Inc., a robotics company developing technology that combines human-like surgical robots and virtual reality to perform minimally invasive surgery, in a pending merger with special purpose acquisition company D8 Holdings Corp. that is expected to deliver up to $460 million in gross proceeds.
Case Study
Mintz is advising DeepGreen Metals Inc., a company developing a new source of electric vehicle battery metals from polymetallic nodules found on the seafloor, in its proposed merger with Sustainable Opportunities Acquisition Corporation, a special purpose acquisition company (SPAC) focused on ESG.
Case Study
Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.
Case Study
Mintz is acting as legal advisor to Quantum-SI Incorporated, developer of a pioneering semiconductor chip to sequence proteins, in its proposed business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP.
Case Study
Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Case Study
Mintz advised Oberon Fuels, a developer of an ultra-low-carbon fuel known as renewable dimethyl ether (rDME), on a strategic collaboration with propane fuel distributor SHV Energy. The agreement will help Oberon scale up its pilot facility to produce the first rDME fuel in the United States.
Case Study
After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.
Case Study
After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).
Case Study
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Case Study
Mintz transactional and health regulatory professionals represented clinical-stage oncology company G1 Therapeutics in its $108.6 million initial public offering (IPO).
Case Study
Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.
Case Study
Mintz helped women’s reproductive health care company Daré Bioscience Operations, Inc. become a wholly owned subsidiary of Cerulean and a publicly traded company named Daré Bioscience, Inc. The innovative deal utilized a variation of a reverse merger into a publicly traded fallen-angel.
Case Study
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.